Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party

This article was originally published in The Pink Sheet Daily

Executive Summary

In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.

You may also be interested in...

Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic

Patent litigation between Par and J&J is pending in Newark, N.J. federal court. Par received ANDA approval for the tramadol/acetaminophen combination the same day the 30-month stay expired.

Teva Legal Challenge Against "Authorized" Generics Rejected By D.C. Court

Any reduction in the economic value of an ANDA first-filer's product during the 180-day exclusivity period "does not rise to the level of absurdity" requiring the court to look beyond the "plain language" of the FD&C Act, D.C. Judge Walton rules. Teva is appealing the decision.

FDA Will Seriously Consider Concerta Petition, J&J Says

FDA will seriously consider Johnson & Johnson's citizen petition filed in an effort to block approval of generic Concerta, the company says

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts